Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최지하 | - |
dc.date.accessioned | 2016-08-28T12:08:25Z | - |
dc.date.available | 2016-08-28T12:08:25Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0009-9236 | - |
dc.identifier.other | OAK-8092 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/222050 | - |
dc.description.abstract | Multidrug and toxin extrusion 2 (MATE2-K (SLC47A2)), a polyspecific organic cation exporter, facilitates the renal elimination of the antidiabetes drug metformin. In this study, we characterized genetic variants of MATE2-K, determined their association with metformin response, and elucidated their impact by means of a comparative protein structure model. Four nonsynonymous variants and four variants in the MATE2-K basal promoter region were identified from ethnically diverse populations. Two nonsynonymous variantsc.485CT and c.1177GAwere shown to be associated with significantly lower metformin uptake and reduction in protein expression levels. MATE2-K basal promoter haplotypes containing the most common variant, g.130GA (26% allele frequency), were associated with a significant increase in luciferase activities and reduced binding to the transcriptional repressor myeloid zinc finger 1 (MZF-1). Patients with diabetes who were homozygous for g.130A had a significantly poorer response to metformin treatment, assessed as relative change in glycated hemoglobin (HbA1c) (0.027 (0.076, 0.033)), as compared with carriers of the reference allele, g.130G (0.15 (0.17, 0.13)) (P = 0.002). Our study showed that MATE2-K plays a role in the antidiabetes response to metformin. © 2011 American Society for Clinical Pharmacology and Therapeutics. | - |
dc.language | English | - |
dc.title | A common 5′-UTR variant in MATE2-K is associated with poor response to metformin | - |
dc.type | Review | - |
dc.relation.issue | 5 | - |
dc.relation.volume | 90 | - |
dc.relation.index | SCI | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 674 | - |
dc.relation.lastpage | 684 | - |
dc.relation.journaltitle | Clinical Pharmacology and Therapeutics | - |
dc.identifier.doi | 10.1038/clpt.2011.165 | - |
dc.identifier.wosid | WOS:000296420700023 | - |
dc.identifier.scopusid | 2-s2.0-80054970528 | - |
dc.author.google | Choi J.H. | - |
dc.author.google | Yee S.W. | - |
dc.author.google | Ramirez A.H. | - |
dc.author.google | Morrissey K.M. | - |
dc.author.google | Jang G.H. | - |
dc.author.google | Joski P.J. | - |
dc.author.google | Mefford J.A. | - |
dc.author.google | Hesselson S.E. | - |
dc.author.google | Schlessinger A. | - |
dc.author.google | Jenkins G. | - |
dc.author.google | Castro R.A. | - |
dc.author.google | Johns S.J. | - |
dc.author.google | Stryke D. | - |
dc.author.google | Sali A. | - |
dc.author.google | Ferrin T.E. | - |
dc.author.google | Witte J.S. | - |
dc.author.google | Kwok P.-Y. | - |
dc.author.google | Roden D.M. | - |
dc.author.google | Wilke R.A. | - |
dc.author.google | McCarty C.A. | - |
dc.author.google | Davis R.L. | - |
dc.author.google | Giacomini K.M. | - |
dc.contributor.scopusid | 최지하(35080057300) | - |
dc.date.modifydate | 20230703145027 | - |